We take a look at the approval of Relyvrio, the third approved treatment for ALS, and the first to show both a slowing of disease progression and extended survival.
More M&A and corporate strategic changes? Advances in Alzheimers? New offerings for NASH & depression? We take a peek into what to expect in pharma in 2023.
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.
Could dostarlima spare some colorectal cancer patients from chemo? Is it possible to predict which CAR-T patients are at risk of CRS? More ASCO highlights.